Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
26.18
+1.75 (+7.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
647,112
Open
24.65
Bid (Size)
26.38 (1)
Ask (Size)
29.15 (1)
Prev. Close
24.43
Today's Range
24.60 - 26.23
52wk Range
13.57 - 53.08
Shares Outstanding
68,600,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Latest Analyst Ratings For Arvinas
July 31, 2024
Via
Benzinga
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-36.92%
-36.92%
1 Month
-11.31%
-11.31%
3 Month
-25.73%
-25.73%
6 Month
-46.34%
-46.34%
1 Year
-3.00%
-3.00%
More News
Read More
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Analyst Ratings For Arvinas
May 17, 2024
Via
Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
Via
Investor's Business Daily
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
July 16, 2024
Via
Benzinga
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024
From
Arvinas Inc.
Via
GlobeNewswire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
June 14, 2024
Via
Talk Markets
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
May 16, 2024
Via
Benzinga
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
May 15, 2024
Via
Benzinga
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024
From
Arvinas Inc.
Via
GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Via
Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.